Edinger Jack D, Manber Rachel, Buysse Daniel J, Krystal Andrew D, Thase Michael E, Gehrman Phillip, Fairholme Christopher P, Luther James, Wisniewski Stephen
Department of Medicine, National Jewish Health, Denver, CO.
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC.
J Clin Sleep Med. 2017 Feb 15;13(2):205-213. doi: 10.5664/jcsm.6448.
To determine if patients with childhood onsets (CO) of both major depression and insomnia disorder show blunted depression and insomnia treatment responses to concurrent interventions for both disorders compared to those with adult onsets (AO) of both conditions.
This study was a secondary analysis of data obtained from a multisite randomized clinical trial designed to test the efficacy of combining a psychological/behavior insomnia therapy with antidepressant medication to enhance depression treatment outcomes in patients with comorbid major depression and insomnia. This study included 27 adults with CO of depression and insomnia and 77 adults with AO of both conditions. They underwent a 16-week treatment including: (1) a standardized two-step pharmacotherapy for depression algorithm, consisting of escitalopram, sertraline, and desvenlafaxine in a prescribed sequence; and (2) either cognitive behavioral insomnia therapy (CBT-I) or a quasi-desensitization control (CTRL) therapy. Main outcome measures were the 17-item Hamilton Rating Scale for Depression (HRSD-17) and the Insomnia Severity Index (ISI) completed pre-treatment and every 2 weeks thereafter.
The AO and CO groups did not differ significantly in regard to their pre-treatment HRSD-17 and ISI scores. Mixed model analyses that adjusted for the number of insomnia treatment sessions attended showed that the AO group achieved significantly lower, subclinical scores on the HRSD-17 and ISI than did the CO group by the time of study exit. Moreover, a significant group by treatment arm interaction suggested that HRSD-17 scores at study exit remained significantly higher in the CO group receiving the CTRL therapy than was the case for the participants in the CO group receiving CBT-I. Greater proportions of the AO group achieved a priori criteria for remission of insomnia (49.3% vs. 29.2%, p = 0.04) and depression (45.5% vs. 29.6%, p = 0.07) than did those in the CO group.
Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders. Further research is needed to identify therapies that enhance the depression and insomnia treatment responses of those with childhood onsets of these two conditions.
确定与成年期起病(AO)的重度抑郁症和失眠症患者相比,童年期起病(CO)的这两种疾病患者对同时针对这两种疾病的干预措施的抑郁和失眠治疗反应是否减弱。
本研究是对一项多中心随机临床试验数据的二次分析,该试验旨在测试将心理/行为失眠疗法与抗抑郁药物联合使用对合并重度抑郁症和失眠症患者抑郁治疗效果的影响。本研究纳入了27名患有抑郁症和失眠症的童年期起病的成年人以及77名患有这两种疾病的成年期起病的成年人。他们接受了为期16周的治疗,包括:(1)标准化的两步抑郁症药物治疗方案,按规定顺序使用艾司西酞普兰、舍曲林和去甲文拉法辛;(2)认知行为失眠疗法(CBT-I)或准脱敏对照(CTRL)疗法。主要结局指标为治疗前及此后每2周完成的17项汉密尔顿抑郁量表(HRSD-17)和失眠严重程度指数(ISI)。
AO组和CO组在治疗前的HRSD-17和ISI评分方面无显著差异。对参加失眠治疗疗程数进行调整的混合模型分析显示,到研究结束时,AO组在HRSD-17和ISI上的得分显著低于CO组,处于亚临床水平。此外,显著的组×治疗组交互作用表明,接受CTRL疗法的CO组在研究结束时的HRSD-17评分仍显著高于接受CBT-I的CO组参与者。与CO组相比,AO组达到失眠缓解(49.3%对29.2%,p = 0.04)和抑郁缓解(45.5%对29.6%,p = 0.07)的先验标准的比例更高。
童年期首次同时出现抑郁症和失眠症的合并症患者对本文提供的治疗的反应不如成年期出现这些合并症的患者。需要进一步研究以确定能够增强童年期出现这两种疾病的患者的抑郁和失眠治疗反应的疗法。